

With HCV Pipeline Crowded, Anadys Acquisition Provides Needed Differentiation

<https://marketpublishers.com/r/WBFC76FC447EN.html>

Date: October 2011

Pages: 7

Price: US\$ 140.00 (Single User License)

ID: WBFC76FC447EN

Abstracts

Roche today announced acquisition of US based Anadys pharmaceuticals for \$230m in cash, which expands its existing Hepatitis C virus franchise. Anadys brings two pipeline candidates, ANA598 -non-nucleoside direct acting antiviral inhibitors (Setrobuvir, PhII, -NS5B inhibitor) and ANA773- Oral small molecule inducer of exogenous interferon (PhI, TLR 7 agonist), the addition of which should allow Roche to pursue interferon free regimen and address the issue of viral resistance. ANA598 seems to be not impacted by viral resistance as it has produced consistent viral response in both treatment naïve and treatment experience patients.

Contents

COMPANIES MENTIONED

I would like to order

Product name: With HCV Pipeline Crowded, Anadys Acquisition Provides Needed Differentiation

Product link: <https://marketpublishers.com/r/WBFC76FC447EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WBFC76FC447EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970